Suppr超能文献

荷兰导管原位癌治疗中放疗使用的去强化——2008年至2022年全国性概述

Deintensification of Radiotherapy Use in Treatment of Ductal Carcinoma In Situ in the Netherlands-A Nationwide Overview From 2008 Until 2022.

作者信息

Evers J, van der Sangen M J C, van Maaren M C, Maduro J H, Strobbe L, Aarts M J, Bloemers M C W M, Wesseling J, van den Bongard D H J G, Struikmans H, Siesling S

机构信息

Netherlands Comprehensive Cancer Organisation (IKNL), Department of Research and Development, Godebaldkwartier 419, 3511 DT Utrecht, the Netherlands; University of Twente, Department of Health Technology and Services Research, Technical Medical Center, Hallenweg 5, 7522 NH Enschede, the Netherlands.

Catharina Hospital, Department of Radiation Oncology, Michelangelolaan 2, 5623 EJ Eindhoven, the Netherlands.

出版信息

Clin Oncol (R Coll Radiol). 2025 Feb;38:103740. doi: 10.1016/j.clon.2024.103740. Epub 2024 Dec 17.

Abstract

AIMS

Ductal Carcinoma In Situ (DCIS) treated by breast-conserving surgery followed by radiotherapy aims to decrease the probability of locally recurrent disease. The role of whole breast irradiation, specifically in DCIS having low recurrence risk and low risk of becoming invasive, is increasingly debated. Also, the added value of applying boost irradiation in DCIS has been questioned. Hence, we evaluated the nationwide radiotherapy use in DCIS treatment in the Netherlands.

MATERIALS AND METHODS

Women diagnosed with DCIS in 2008-2022 were identified in the Netherlands Cancer Registry. Their primary treatment was presented over time and for age groups, stratified for DCIS grade I-II and III. Factors associated with radiotherapy use after breast-conserving surgery and boost irradiation use in whole breast irradiation after breast-conserving surgery were identified.

RESULTS

In women with DCIS grade I-II (N = 16,653), the use of breast-conserving surgery without radiotherapy increased from ∼11% in 2008-2013 to ∼26% in 2017-2022. Furthermore, post-breast-conserving surgery radiotherapy increasingly concerned whole breast irradiation without a boost or partial breast irradiation. Moreover, surgery was omitted more often in recent years (30% in 2022). In DCIS grade III (N = 13,534), the use of breast-conserving surgery without radiotherapy only slightly increased in the most recent years in older patients, while boost irradiation was increasingly omitted. Whole breast irradiation and boost irradiation following breast-conserving surgery were more often applied in case of a higher risk of recurrences: young age, larger lesions, or irradical resection. Variation was observed for hospital-characteristics but not for regions.

CONCLUSION

In DCIS, the process of omitting breast irradiation after breast-conserving surgery is clearly ongoing. Boost irradiation was administered less frequently. Furthermore, the use of partial breast irradiation was introduced in recent years. These effects are more prominent in older women and those with grade I-II DCIS.

摘要

目的

保乳手术加放疗治疗导管原位癌(DCIS)旨在降低局部复发疾病的概率。全乳照射的作用,特别是在复发风险低且侵袭风险低的DCIS中,越来越受到争议。此外,在DCIS中应用瘤床加量照射的附加价值也受到质疑。因此,我们评估了荷兰全国范围内DCIS治疗中放疗的使用情况。

材料与方法

在荷兰癌症登记处确定2008年至2022年期间诊断为DCIS的女性。按时间和年龄组呈现她们的初始治疗情况,并按DCIS I-II级和III级分层。确定了保乳手术后放疗使用以及保乳手术后全乳照射中瘤床加量照射使用的相关因素。

结果

在I-II级DCIS女性(N = 16,653)中,未进行放疗的保乳手术使用率从2008 - 2013年的约11%增加到2017 - 2022年的约26%。此外,保乳手术后放疗越来越多地涉及无瘤床加量的全乳照射或部分乳腺照射。而且,近年来手术被省略的情况更频繁(2022年为30%)。在III级DCIS(N = 13,534)中,老年患者中未进行放疗的保乳手术使用率在最近几年仅略有增加,而瘤床加量照射越来越多地被省略。保乳手术后全乳照射和瘤床加量照射在复发风险较高的情况下更常应用:年轻、病变较大或切除不彻底。观察到医院特征存在差异,但地区间无差异。

结论

在DCIS中,保乳手术后省略乳腺照射的过程显然正在进行。瘤床加量照射的使用频率降低。此外,近年来引入了部分乳腺照射。这些影响在老年女性和I-II级DCIS患者中更为突出。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验